Mei Ri Jing Ji Xin Wen·2025-11-06 13:04Core Viewpoint - BeiGene reported a significant increase in revenue and net profit for the first three quarters of 2025, driven by strong sales of its self-developed and licensed products [1] Financial Performance - Total revenue for the first three quarters reached 27.595 billion, marking a year-on-year growth of 44.2% [1] - Net profit attributable to the parent company was 1.139 billion [1] Product Sales - Sales of the self-developed product, Brukinsa® (Zebutinib capsules), totaled 7.423 billion, reflecting a year-on-year increase of 51.0%, leading the global market for BTK inhibitors [1] - Sales of the licensed product, Tislelizumab injection (百泽安®), amounted to 1.363 billion, with a year-on-year growth of 16.6% [1] Future Projections - The company anticipates total revenue for 2025 to be between 36.2 billion and 38.1 billion [1] - Combined R&D, sales, and management expenses are projected to be between 29.5 billion and 30.9 billion [1] - Gross margin is expected to remain in the mid-to-high range of 80% to 90% [1]